Kura Oncology Inc reports a Return on Equity (ROE) of -273.05%.

What is KURA's dividend yield?

Kura Oncology Inc offers a dividend yield of 0.00%.

What is KURA's Quality Score?

Our AI rates KURA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KURA?

Our AI Timing Score for KURA is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KURA belong to?

Kura Oncology Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Kura Oncology Inc (KURA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

KURA AI Analysis Summary

Our AI summary for KURA: Kura Oncology Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -273.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KURA

Kura Oncology Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 9.47

0.28 (3.05%) Day Change

Watchlist Portfolio Compare Chart

0.10

D/E

-273.1%

ROE

-45.1%

ROA

0.00%

Div Yield

KURA ONCOLOGY INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 9.47 Price 0.28 (3.05%) Day Change	NEWS SCORE: N/A

KURA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	9.47
PBV / Sector	7.56 / 44,022.72
Earning Per Share	-3.42

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	12.95 M GREAT
Average 1W Daily Value	11.95 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-411.19 / 98.24
NPM Average (%) / Sector	-382.34 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-45.14 / 185,260.96
ROA Average (%) / Sector	-33.91 / 36,684.70
ROA Change Average (%) / Sector	16.51 / 422,221.66 GOOD
ROE (%) / Sector	-273.05 / 243,762.23
ROE Average (%) / Sector	-109.18 / 48,758.47
ROE Change Average (%) / Sector	94.86 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:27
Symbol	KURA
Name	KURA ONCOLOGY INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	88.77 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	815.84 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4930 Directors Place, San Diego, CA, United States, 92121

Phone: 858 500 8800

Website: https://kuraoncology.com

Employees: 260

Sector: Healthcare >> Biotechnology

Description: Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.